Tiny Implant Uses Catalyst to Lower Blood Sugar in Diabetes Treatment

Type 2 diabetes is becoming increasingly common worldwide. Unlike type 1 diabetes, it is often linked to obesity, a sedentary lifestyle and excess energy intake over many years. Although insulin injections can bring blood sugar levels down, they do not address the body's chronic energy surplus.

Insulin merely helps muscle cells take up glucose from the bloodstream, but if the body does not use that energy, the excess is converted into fat. This helps explain why many patients continue to gain weight despite treatment. Now, a team led by Martin Fussenegger has developed a potential new way to treat diabetes: an implantable system that uses an electrically powered catalyst to lower blood glucose.

Fussenegger is a professor in ETH Zurich's Department of Biosystems Science and Engineering in Basel. The team's findings have been published in Science . New approach uses electronics instead of biomolecules For years, the Basel-based team of researchers has been exploring ways to tackle diabetes with systems that regulate blood sugar.

Earlier approaches relied on specially developed genetic networks. However, these systems depend on biological components, which pose additional challenges in areas such as immune tolerance, stability, manufacturing and regulatory approval. The new system gets around this problem with a catalyst made entirely from inorganic materials, which needs no cells, enzymes or other biological components.

It consists of graphite felt studded with gold nanoclusters, which are themselves decorated with even smaller platinum particles. The materials showed excellent biocompatibility in the experimental study, says Fussenegger. The team developed the catalyst's nanostructured surface themselves.

The implant also contains an electronic control unit housed in a 3D-printed casing. Power is supplied wirelessly at a frequency of 13.56 MHz, which is internationally designated for industrial, scientific and medical applications. Converting glucose into gluconate The catalyst converts excess glucose in the blood into gluconate.

This means that some of the glucose is no longer metabolised and stored in tissue, which also helps limit the build-up of body fat. The gluconate is then excreted in the urine. The catalyst is controlled wirelessly through a closed-loop system.

A standard glucose sensor, like those commonly worn on the upper arm by people with diabetes, continuously monitors glucose levels in the tissue. If blood sugar rises too high after a meal, the sensor sends a signal via Bluetooth to a smartphone or smartwatch. The smart device then activates the catalyst, which uses electrical energy to convert the glucose.

Once glucose levels have fallen to the desired level, the device switches itself off automatically, protecting patients from dangerously low blood sugar. Successfully tested in mice In a laboratory experiment, Fussenegger's team tested the system in a reservoir holding 5 litres of a glucose-containing nutrient solution – roughly the volume of blood in the human body.

This showed that the catalyst was capable of converting glucose in this volume of solution. The researchers also tested the system in diabetic mice and found that the animals' blood sugar could be precisely regulated. The mice lost weight, the implant was well tolerated and it operated reliably during a six-week period.

"The system operates at a very low voltage, and our experiments showed no evidence of tissue damage from either electrical or thermal effects," says Fussenegger. The team has not yet tested the device on humans. Paradigm shift: from conventional drugs to an electronic device Fussenegger sees the approach as a paradigm shift away from conventional drugs and towards scalable, electronically controlled treatments that can be integrated into digital environments such as the Internet of Things.

" For decades, we have treated diabetes by telling the body how to manage glucose. We are now showing that we can take control of glucose directly, using electronics rather than drugs," he says. "And the catalyst only activates when glucose levels are too high." The team now plans to develop the system into a medical device.

Because the glucose-lowering mechanism itself works without cells or enzymes, technical development could be more straightforward. Another advantage is that the components needed to build such a device, including external control and wireless power transmission devices, have already been developed and are commercially available. /Public Release.

This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here .